Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral Oseltamivir
Status:
Completed
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, randomised, four arms placebo controlled study to evaluate the safety
and tolerability of 10 mg inhaled zanamivir once a day and 75 mg oseltamivir capsule orally
once a day relative to placebo over 16 weeks (112 days). Enrolled subjects will be randomly
assigned to 2:1:2:1 ratio (active oseltamivir: placebo: active zanamivir: placebo) on one of
the four study treatment groups.
It is hypothesized that oseltamivir and zanamivir will protect participants from becoming
infected with influenza.
Phase:
Phase 4
Details
Lead Sponsor:
University of Oxford
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)